Loading organizations...
Based in Boston, Massachusetts, the Estate of Henri Termeer operates primarily through The Termeer Foundation, a nonprofit organization dedicated to connecting life science innovators and catalyzing the development of new medicines for rare diseases. The organization operates with a core team of approximately 28 employees and relies on philanthropic donations to fund its various mentorship programs and healthcare initiatives. Focusing on the biotechnology and orphan drug sectors, the estate honors the legacy of former Genzyme chief executive officer Henri Termeer by supporting emerging corporate leaders in drug development. The organization manages the Termeer Fellows program to mentor next-generation executives and collaborated on the 2020 dedication of Henri A. Termeer Square in Cambridge's Kendall Square. The foundation was established in 2017 by co-founders Belinda Termeer and Alan Walts alongside a broader group of biotechnology executives.
Estate of Henri Termeer has 1 tracked investment across 1 company. The latest tracked deal is $75.0M Series B in Arrakis Therapeutics in April 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 1, 2019 | Arrakis Therapeutics | $75.0M Series B | Jakob Loven | 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, HealthQuest Capital, Nextech Invest, OrbiMed, RA Capital, VenBio Partners, Advent Life Sciences, Alexandria Venture Investments, Canaan Partners, Celgene, GV, HBM Healthcare Investments, Omega Funds, Osage University Partners, WuXi AppTec |